The relationship between hormonal contraceptive method use and sexually transmitted infections is not well understood. Studies that implement routine screening for STIs among different contraceptive users, such as the ASPIRE HIV-1 prevention trial, can be useful for identifying potential risk factors of STIs. However, the complex nature of non-random data can lead to challenges in estimation of associations for potential risk factors. In particular, if screening for the disease is not random (i. e. it is driven by symptoms or other clinical indicators), estimates of association can suffer from bias, often referred to as informative sampling bias. Time-varying predictors and potential stratification variables can further contribute to difficulty in obtaining unbiased estimates. In this paper, we estimate the association between time- varying contraceptive use and Sexually transmitted infections acquisition, in the presence of informative sampling, by extending the work Buzkova (2010). We use a two-step procedure to jointly model the non-random screening process and sexually transmitted infection risk. In the first step, inverse intensity rate ratios (IIRR) weights are estimated. In the second step, a weighted proportional rate model is fit to estimate the IIRR weighted hazard ratio. We apply the method to evaluate the relationship between hormonal contraception and risk of sexually transmitted infections among women participating in a biomedical HIV-1 prevention trial. We compare our results using the proposed weighted method to those generated using conventional approaches that do not account for potential informative sampling bias or do not use the full potential of the data. Using the IIRR weighted approach we found depot medroxyprogesterone acetate users have a significantly decreased hazard of Trichomonas vaginalis acquisition compared to IUD users (hazard ratio: 0.44, 95% CI: (0.25, 0.83)), which is consistent with the literature. We did not find significant increased or decreased hazard of other STIs for hormonal contraceptive users compared to non-hormonal IUD users.
Funding source: National Institute of Allergy and Infectious Diseases
Award Identifier / Grant number: UM1AI068615UM1AI068633UM1AI106707
We thank the study participants for their dedication to the ASPIRE trial. We acknowledge the study staff and investigators from the MTN sites; and appreciate the support of the ASPIRE co-chairs and team, and the MTN leadership. ASPIRE Study Team Leadership: Jared Baeten, University of Washington (Protocol Chair); Thesla Palanee-Phillips, Wits Reproductive Health and HIV Institute (Protocol Co-chair); Elizabeth Brown, Fred Hutchinson Cancer Research Center (Protocol Statistician); Lydia Soto-Torres, US National Institute of Allergy and Infectious Diseases (Medical Officer); Katie Schwartz, FHI 360 (Clinical Research Manager). Study sites and site Investigators of Record: Malawi, Blantyre site (Johns Hopkins University, Queen Elizabeth Hospital): Bonus Makanani; Malawi, Lilongwe site (University of North Carolina, Chapel Hill): Francis Martinson and Lameck Chinula; South Africa, Cape Town site (University of Cape Town): Linda-Gail Bekker; South Africa, Durban – Botha’s Hill, Chatsworth, Isipingo, Tongaat, Umkomaas, Verulam sites (South African Medical Research Council): Vaneshree Govender, Samantha Siva, Zakir Gaffoor, Logashvari Naidoo, Arendevi Pather, Bomkazi Tutshana, Jayajothi Moodley, Kubashini Woeber, and Nitesha Jeenarain; South Africa, Durban, eThekwini site (Center for the AIDS Programme for Research in South Africa): Gonasagrie Nair and Leila Mansoor; South Africa, Johannesburg site (Wits Reproductive Health and HIV Institute, University of the Witwatersrand ): Thesla Palanee-Phillips; Uganda, Kampala site (John Hopkins University, Makerere University): Flavia Matovu Kiweewa and Clemensia Nakabiito; Zimbabwe, Chitungwiza, Seke South and Zengeza sites (University of Zimbabwe College of Health Sciences Clinical Trials Research Centre): Nyaradzo Mgodi, Zimbabwe, Harare, Spilhaus site (University of Zimbabwe College of Health Sciences Clinical Trials Research Centre): Felix Mhlanga, Data management was provided by the Statistical Center for HIV/AIDS Research & Prevention (Fred Hutchinson Cancer Research Center, Seattle, WA) and site laboratory oversight was provided by the Microbicide Trials Network Laboratory Center (Pittsburgh, PA).
Fund source: National Institute of Allergy and Infectious Diseases.
Grant numbers: UM1AI068633, UM1AI068615, UM1AI106707, UM1AI148684.
Research funding: This work was supported by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health (NIH).
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Ethical statements are mandatory for original research that involved human or animal subjects.
Appendix A: Derivation of estimating equation
For individual i at time t define Xi(t) define to be the time-varying predictor of interest. Suppose there is a population of size n with i = 1, … n. Let Ni(t) and dNi(t) be the cumulative event process and indicator of event as defined above. Let and be the cumulative screening process and indicator of screening as defined above. Let Yi(t) be a censoring indicator, such that Yi(t) = 1 when the ith person remains in the risk set at time t. For convenience, we will use the subscript k to denote membership to the kth stratum, with k having levels i = 1,2, … ,K. Let subjects i = 1, … ,nk be in the subjects belonging to the kth stratum.
The zero-mean process used to estimate β, the p-length vector of associations between the repeated outcome and exposure , is
where K is the total number of stratum, nk is the sample size for stratum k, and subscript k denotes membership to stratum k. This zero-mean process is the same as in Buzkova (2010), with the change that exposure of interest now depends on time t. The corresponding score function is
Since STI diagnosis (i. e. dNi,k = 1) can only occur at visits where the participant was observed (i. e. ) there is only contribution to the estimating equation when both . Therefore Eq. (7) simplifies to
Equation (8) is the proposed estimating equation that provides the IIRR weighted estimator for β, when time-varying covariates and stratification covariates are included in the model.
Appendix B: Example R code
Code for implementing IIRR weighted method is publicly available on https://github.com/amishra11/informSamp.git.
The The R code for obtaining inverse intensity rate ratio-weights is as follows:
gamma.hat < - coxph(Surv(start.time, stop.time, visit) ∼ Z, data = dat)$coef delta.hat < - coxph(Surv(start.time, stop.time, visit) ∼ X, data = dat)$coef iirr < - exp(Z %*% gamma.hat)/exp(X %*% delta.hat)
The R code for obtaining inverse intensity rate ratio-weighted estimate of association is as follows:
mod < - informSampHaz(outcome exposure, weight = iirr, id = ptid, time = time, strata = strat, data = dat)
iirr.hazRatio < - exp(mod$beta.hat)
Appendix C: Description of weights
|>1 Sex Partner at Baseline||−0.19||−0.17|
|Reported Condom-less Sex at Baseline||−0.02||−0.04|
|Abnormal Pelvic Findings at Baseline||0.20||–|
|Abnormal Vaginal Discharge at Baseline||−0.10||–|
|>1 Sex Partner During Follow-up (Lagged)||0.11||–|
|Reported Condom-less Sex During Follow-up (Lagged)||0.07||–|
|Change in Primary Sex Partner During Follow-up (Lagged)||−0.70||–|
|Abnormal Pelvic Findings During Follow-up (Lagged)||0.34||–|
|Abnormal Vaginal Discharge During Follow-up (Lagged)||0.28||–|
|Observed Uterine or Adnexal tenderness During Follow-up (Lagged)||−0.09||–|
|C. trachomatis Diagnoses During Follow-up (Lagged)||0.15||–|
|N. gonorrhoeae Diagnoses During Follow-up (Lagged)||−0.10||–|
|T. vaginalis Diagnoses During Follow-up (Lagged)||0.17||–|
|Active Drug Study Arm||–||0.05|
Alkema, L., V. Kantorova, C. Menozzi, and A. Biddlecom. 2013. “National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis.” The Lancet 381: 1642–1652. https://doi.org/10.1016/s0140-6736(12)62204-1.Search in Google Scholar
Andersen, P. K. and R. D. Gill. 1982. “Cox’s regression model for counting processes: a large sample study.” The annals of statistics: 1100–1120. https://doi.org/10.1214/aos/1176345976.Search in Google Scholar
Baeten, J. M., P. M. Nyange, B. A. Richardson, L. Lavreys, B. Chohan, H. L. Martin, K. Mandaliya, J. O. Ndinya-Achola, J. J. Bwayo, and J. K. Kreiss. 2001. “Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.” American Journal of Obstetrics & Gynecology 185: 380–385. https://doi.org/10.1067/mob.2001.115862.Search in Google Scholar
Baeten, J. M., T. Palanee-Phillips, E. R. Brown, K. Schwartz, L. E. Soto-Torres, V. Govender, N. M. Mgodi, F. Matovu Kiweewa, G. Nair, F. Mhlanga, et al.. 2016. “Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.” New England Journal of Medicine 375: 2121–2132. https://doi.org/10.3410/f.726166218.793526926.Search in Google Scholar
Borgdorff, H., M. C. Verwijs, F. W. Wit, E. Tsivtsivadze, G. F. Ndayisaba, R. Verhelst, F. H. Schuren, and J. H. van de Wijgert. 2015. “The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers.” Sexually transmitted diseases 42: 143–152. https://doi.org/10.1097/olq.0000000000000245.Search in Google Scholar
Buzkova, P. and T. Lumley. 2007. “Longitudinal data analysis for generalized linear models with follow-up dependent on outcome-related variables.” Canadian Journal of Statistics 35: 485–500. https://doi.org/10.1002/cjs.5550350402.Search in Google Scholar
Gursahaney, P. R., L. A. Meyn, S. L. Hillier, R. L. Sweet, and H. C. Wiesenfeld. 2010. “Combined hormonal contraception may be protective against neisseria gonorrhoeae infection.” Sexually Transmitted Diseases 37: 356–360. https://doi.org/10.1097/olq.0b013e3181d40ff1.Search in Google Scholar
Liang, Y., W. Lu, and Z. Ying. 2009. “Joint modeling and analysis of longitudinal data with informative observation times.” Biometrics 65: 377–384. https://doi.org/10.1111/j.1541-0420.2008.01104.x.Search in Google Scholar
Lin, D. and Z. Ying. 2001. “Semiparametric and nonparametric regression analysis of longitudinal data.” Journal of the American Statistical Association 96: 103–126. https://doi.org/10.1198/016214501750333018.Search in Google Scholar
Matovu, F., E. Brown, A. Mishra, G. Nair, T. Palanee-Phillips, N. Mgodi, C. Nakabiito, N. Chakhtoura, S. Hillier, and J. Baeten. 2017. “Acquisition of sexually transmitted infections among women using a variety of contraceptive options: a prospective study among high-risk African women.” Journal of the International AIDS Society 23: 94–95. https://doi.org/10.1002/jia2.25257.Search in Google Scholar
Mohllajee, A. P., K. M. Curtis, S. L. Martins, and H. B. Peterson. 2006. “Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review.” Contraception 73: 154–165. https://doi.org/10.1016/j.contraception.2005.08.012.Search in Google Scholar
Morrison, C. S., A. N. Turner, and L. B. Jones. 2009. “Highly effective contraception and acquisition of HIV and other sexually transmitted infections.” Best practice & research Clinical obstetrics & gynaecology 23: 263–284. https://doi.org/10.1016/j.bpobgyn.2008.11.004.Search in Google Scholar
Newman, L., J. Rowley, S. Vander Hoorn, N. S. Wijesooriya, M. Unemo, N. Low, G. Stevens, S. Gottlieb, J. Kiarie, and M. Temmerman. 2015. “Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting.” PloS one 10: e0143304. https://doi.org/10.1371/journal.pone.0143304.Search in Google Scholar
Pettifor, A., S. Delany, I. Kleinschmidt, W. C. Miller, J. Atashili, and H. Rees. 2009. “Use of injectable progestin contraception and risk of STI among South African women,” Contraception 80: 555–560. https://doi.org/10.1016/j.contraception.2009.06.007.Search in Google Scholar
Song, X., X. Mu, and L. Sun. 2012. “Regression analysis of longitudinal data with time-dependent covariates and informative observation times.” Scandinavian Journal of Statistics 39: 248–258. https://doi.org/10.1111/j.1467-9469.2011.00776.x.Search in Google Scholar
Tan, K. S., B. French, and A. B. Troxel. 2014. “Regression modeling of longitudinal data with outcome-dependent observation times: extensions and comparative evaluation.” Statistics in medicine 33: 4770–4789. https://doi.org/10.1002/sim.6262.Search in Google Scholar
© 2020 Walter de Gruyter GmbH, Berlin/Boston